Total Payments
$2.0M
2024 Payments
$171,164
Companies
62
Transactions
1,439
Medicare Patients
4,464
Medicare Billing
$441,767
Payment Breakdown by Category
Research$1.2M (62.5%)
Consulting$422,999 (21.2%)
Other$178,428 (8.9%)
Travel$89,010 (4.5%)
Food & Beverage$30,790 (1.5%)
Education$28,179 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 147 | 62.5% |
| Consulting Fee | $422,999 | 147 | 21.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $142,613 | 129 | 7.1% |
| Travel and Lodging | $89,010 | 304 | 4.5% |
| Honoraria | $35,815 | 14 | 1.8% |
| Food and Beverage | $30,790 | 685 | 1.5% |
| Education | $28,179 | 13 | 1.4% |
Payments by Type
Research
$1.2M
147 transactions
General
$749,407
1,292 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $633,363 | 6 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $350,643 | 7 | $0 (2017) |
| PFIZER INC. | $124,938 | 123 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $94,317 | 137 | $0 (2024) |
| Eli Lilly and Company | $88,371 | 37 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $74,944 | 150 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $62,266 | 56 | $0 (2024) |
| Amgen Inc. | $60,597 | 49 | $0 (2024) |
| UCB, Inc. | $44,001 | 57 | $0 (2024) |
| Janssen Biotech, Inc. | $43,887 | 93 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $171,164 | 293 | Boehringer Ingelheim International GmbH ($45,173) |
| 2023 | $107,960 | 179 | Boehringer Ingelheim International GmbH ($15,075) |
| 2022 | $146,359 | 161 | Boehringer Ingelheim Pharmaceuticals, Inc. ($24,434) |
| 2021 | $172,741 | 158 | Amgen Inc. ($43,746) |
| 2020 | $95,090 | 84 | PFIZER INC. ($33,999) |
| 2019 | $123,337 | 185 | Eli Lilly and Company ($36,555) |
| 2018 | $730,561 | 203 | Bausch Health US, LLC ($617,500) |
| 2017 | $451,231 | 176 | Valeant Pharmaceuticals North America LLC ($350,643) |
All Payment Transactions
1,439 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Xolair (Biological) | — | In-kind items and services | $3,727.50 | Research |
| Study: Phase III Clinical Trials for Omalizumab and Remibrutinib for Patients With Chronic Spontaneous Urticaria • Category: Immunology | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $232.67 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $217.24 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $217.24 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $217.24 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $199.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $199.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $179.43 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $7.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.79 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.79 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Amgen Inc. | Otezla (Drug) | Consulting Fee | Cash or cash equivalent | $1,983.00 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Amgen Inc. | Otezla (Drug) | Consulting Fee | Cash or cash equivalent | $1,983.00 | General |
| Category: Inflammation | ||||||
| 12/19/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $38.90 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Consulting Fee | Cash or cash equivalent | $2,188.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $41.87 | General |
| Category: DERMATOLOGY | ||||||
| 12/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $341.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $298.71 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: DERMATOLOGY | ||||||
| 12/03/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $6,075.00 | General |
| 12/03/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $993.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2017-2784 Lebwohl | Bausch Health US, LLC | $567,500 | 4 |
| 2017-2784 Lebwohl | Valeant Pharmaceuticals North America LLC | $350,000 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $68,140 | 2 |
| 2017-2874 Lebwohl | Bausch Health US, LLC | $50,000 | 1 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $21,420 | 18 |
| 2019-5041 - Lebwohl | Bausch Health US, LLC | $15,863 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $12,650 | 11 |
| CC-10004-PSOR-012 | Celgene Corporation | $12,642 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAI | UCB, Inc. | $10,920 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $10,355 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,808 | 16 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,413 | 8 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,880 | 5 |
| EVOLUTION OF PATIENT PERCEPTIONS OF PSORIATIC DISEASE: RESULTS FROM THE UNDERSTANDING PSORIATIC DISEASE LEVERAGING INSIGHTS FOR TREATMENT (UPLIFT) SURVEY | Amgen Inc. | $6,908 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJ | UCB, Inc. | $6,400 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $5,346 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $4,850 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $4,360 | 6 |
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to | UCB, Inc. | $4,360 | 5 |
| Phase III Clinical Trials for Omalizumab and Remibrutinib for Patients With Chronic Spontaneous Urticaria | F. Hoffmann-La Roche AG | $3,728 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $3,660 | 9 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFIC | UCB, Inc. | $3,540 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $3,450 | 1 |
| Patient Perceptions of Psoriatic Disease in Five European Countries: Results From the European Subgr | Amgen Inc. | $3,250 | 1 |
| Infrequent Healthcare Professional Appointments Despite High Levels of Disease Burden in Psoriatic | Amgen Inc. | $3,164 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS W | UCB, Inc. | $3,120 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE-CONTROLLED STUDY FOLLOWED BY A PLACEBOCONTROLLED MAINTENANCE PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB, Inc. | $2,300 | 1 |
| A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17 | UCB, Inc. | $2,300 | 1 |
| Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Su | Amgen Inc. | $2,109 | 1 |
| A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | Celgene Corporation | $2,096 | 1 |
| Patient Perceptions of Psoriatic Disease in the United States: Results From the US Subgroup of the U | Amgen Inc. | $2,043 | 1 |
| Ph4 Otezla in oligoarticular PsA FOREMOST/KEG | Amgen Inc. | $2,037 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,995 | 2 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AT 16 WEEKS OF TREATMENT COMPARED TO USTEKINUMAB AND TO ASSESS LONG TERM SAFETY TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Novartis Pharmaceuticals Corporation | $1,928 | 1 |
| Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Patient Characteristics and Disease Burden Findings From CorEvitas Psoriasis Registry CorEvitas Poster | Amgen Inc. | $1,796 | 1 |
| Greater Disease Burden in Patients With Psoriasis Who Report Joint Pain Without a Diagnosis of Psoriatic Arthritis: Results From the 2020 UPLIFT Survey UPLIFT PSO MSK Poster | Amgen Inc. | $1,796 | 1 |
| Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Dise | Amgen Inc. | $1,712 | 1 |
| Characteristics and Disease Burden in Patients With Mild to Moderate vs Severe Plaque Psoriasis in | Amgen Inc. | $1,588 | 1 |
| CLOU064A2301- REMIX-1,CLOU064A2302-REMIX-2 | Novartis Pharmaceuticals Corporation | $1,553 | 1 |
| EADV 2020 Target PASI Achievement by Treatment History Abstract | Amgen Inc. | $1,441 | 1 |
| EADV 2020 Target PASI Achievement by Treatment History Poster | Amgen Inc. | $1,430 | 1 |
| EADV 2020 Target PASI and Specific Manifestations and Symptoms Poster | Amgen Inc. | $1,430 | 1 |
| Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas' Psoriasis Registry | Amgen Inc. | $1,347 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKI | UCB, Inc. | $1,240 | 1 |
| Infrequent Healthcare Professional Appointments Despite High Levels of Disease Burden in Psoriatic A | Amgen Inc. | $1,212 | 1 |
| Differences in Patient and Dermatologist Perspectives on Psoriasis Treatment: Results From the UPLIFT Survey UPLIFT Disconnect Oral Presentation | Amgen Inc. | $1,097 | 1 |
| AAD 2020 PASI Pooled Response Poster | Amgen Inc. | $1,082 | 1 |
| EADV 2020 UPLIFT Late Breaker Abstract | Amgen Inc. | $1,005 | 1 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $967.00 | 1 |
| THE EVOLVING TREATMENT APPROACH OF SECUKINUMAB IN BIOLOGIC-EXPERIENCED AND BIOLOGIC-NAIVE PATIENTS WITH PSORIASIS: KEY CLINICAL AND PATIENT CHARACTERISTICS BY YEAR OF TREATMENT INITIATION IN A US-BASED REGISTRY | Novartis Pharmaceuticals Corporation | $964.00 | 1 |
| Impact of Psoriasis in Special Areas on Patient Quality-of-Life Outcomes and Depression Screening: Findings From the Multinational UPLIFT Survey UPLIFT DLQI Abstract | Amgen Inc. | $893.11 | 1 |
| Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Pa | Amgen Inc. | $861.00 | 1 |
| Greater Disease Burden in Patients With Psoriasis Who Report Joint Pain Without a Diagnosis of Psor | Amgen Inc. | $861.00 | 1 |
| Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results | Amgen Inc. | $808.27 | 1 |
| Relationship Between Skin Involvement and Disease Burden in Patients With Mild to Moderate Plaque Psoriasis: Real-World Findings From CorEvitas Psoriasis Registry CorEvitas Abstract | Amgen Inc. | $790.80 | 1 |
| AAD 2021 Corrona Mild-Moderate BOD Abstract | Amgen Inc. | $783.22 | 1 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $750.00 | 2 |
| Differences in Patient and Dermatologist Perspectives on Psoriasis Treatment: Results From the UPLI | Amgen Inc. | $646.00 | 1 |
| WCDC 2021 UPLIFT Abstract | Amgen Inc. | $595.44 | 1 |
| Phase 3 Efficacy and Safety in Moderate to Severe Plaque Psoriasis | Amgen Inc. | $578.00 | 1 |
| Characterizing Musculoskeletal Disease Burden in Mild/Moderate Psoriasis Patients Suggestive of Com | Amgen Inc. | $556.00 | 1 |
| CC-10004-SPSO-001 - A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) | Celgene Corporation | $442.00 | 1 |
| IMPACT OF SECUKINUMAB ON CLINICAL AND PATIENT REPORTED OUTCOMES IN PATIENTS WITH PSORIASIS IN A REAL WORLD SETTING IN THE US | Novartis Pharmaceuticals Corporation | $407.00 | 1 |
| CLOU064A2301,CLOU064A2302 | Novartis Pharmaceuticals Corporation | $356.50 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $282.38 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
| LONG TERM STUDY LEO 90100 ON THE BODY | LEO Pharma AS | $76.41 | 1 |
| Deucravacitinib Ineligibility Map | Amgen Inc. | $25.42 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 8 | 406 | 488 | $151,090 | $30,918 |
| 2021 | 22 | 1,974 | 5,974 | $887,212 | $237,847 |
| 2020 | 21 | 2,084 | 7,569 | $810,152 | $173,002 |
Total Patients
4,464
Total Services
14,031
Medicare Billing
$441,767
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 179 | 202 | $86,620 | $17,050 | 19.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 53 | 58 | $14,850 | $5,162 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 56 | $16,350 | $3,131 | 19.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 41 | 43 | $11,610 | $1,896 | 16.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $8,750 | $1,585 | 18.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 19 | 26 | $4,720 | $1,152 | 24.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 30 | 74 | $5,550 | $477.36 | 8.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 14 | $2,640 | $464.91 | 17.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 593 | 882 | $379,260 | $99,286 | 26.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 234 | 300 | $78,000 | $28,797 | 36.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 298 | 337 | $97,730 | $26,392 | 27.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 111 | 111 | $73,260 | $15,938 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 59 | 71 | $41,180 | $11,588 | 28.1% |
| 96574 | Application of light and light-sensitive drugs following removal of premalignant thickened skin growth, per day | Office | 2021 | 30 | 33 | $22,308 | $9,426 | 42.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 117 | 146 | $39,420 | $7,116 | 18.1% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 45 | 49 | $19,600 | $6,217 | 31.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 28 | 28 | $23,240 | $5,769 | 24.8% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 62 | 96 | $16,320 | $5,012 | 30.7% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2021 | 22 | 3,407 | $7,284 | $4,327 | 59.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 91 | 99 | $17,820 | $4,321 | 24.2% |
| 17262 | Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs | Office | 2021 | 19 | 21 | $14,910 | $3,501 | 23.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 29 | 29 | $12,760 | $2,757 | 21.6% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 14 | 15 | $6,750 | $1,547 | 22.9% |
| 17261 | Destruction of malignant growth (0.6 to 1.0 centimeters) of trunk, arms, or legs | Office | 2021 | 11 | 12 | $7,080 | $1,463 | 20.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 75 | 193 | $14,475 | $1,205 | 8.3% |
About Mark Lebwohl
Mark Lebwohl is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013902444.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Lebwohl has received a total of $2.0M in payments from pharmaceutical and medical device companies, with $171,164 received in 2024. These payments were reported across 1,439 transactions from 62 companies. The most common payment nature is "" ($1.2M).
As a Medicare-enrolled provider, Lebwohl has provided services to 4,464 Medicare beneficiaries, totaling 14,031 services with total Medicare billing of $441,767. Data is available for 3 years (2020–2022), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 09/12/2005
- Last Updated 04/12/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1013902444
Products in Payments
- SILIQ (Drug) $985,366
- Otezla (Drug) $66,824
- COSENTYX (Biological) $56,578
- EUCRISA (Drug) $53,440
- CIBINQO (Drug) $33,976
- SPEVIGO (Drug) $33,141
- TREMFYA (Drug) $32,604
- ILUMYA (Biological) $30,135
- Xolair (Biological) $19,394
- ENSTILAR (Drug) $16,841
- Tremfya (Drug) $15,034
- Enbrel (Biological) $12,552
- OPZELURA (Drug) $10,778
- YCANTH (Drug) $8,866
- TALTZ (Drug) $8,594
- DUPIXENT (Biological) $8,053
- Impoyz (Drug) $7,121
- Sotyktu (Drug) $6,472
- VALCHLOR (Drug) $6,300
- PICATO (Drug) $6,008
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Mr. Michael Cameron
Dermatology — Payments: $1.9M
Dermatology $1.9M